Introduction
The standard treatment for status epilepticus (SE) in Europe is benzodiazepines in treatment stage one, which is followed by phenytoin or its equivalents in treatment stage two, and in refractory cases sedation and intensive care in treatment stage three. 1, 2 This treatment regime carries risks, especially for certain patient categories. For instance, phenytoin is associated with circulatory side effects, which makes the drug unsuitable for frail, elderly, or cardiologically compromised patients. Other antiepileptic drugs (AED) such as valproic acid, levetiracetam (LEV), and lacosamide have therefore attracted interest as alternative stage two AEDs in cases where phenytoin is not appropriate due to allergy or comorbidities. 1 LEV is one of the newer AEDs. Introduced in 1999, the drug has achieved rapid spread in clinical practice, due in large part to its pharmacological properties (e.g. minimal protein-binding and drug-drug interactions). 3 Compared to many other AEDs, LEV has fewer reported major side effects, although this may be a consequence of its relatively short period of clinical use. Some years ago, reports on the use of LEV as an add-on therapy in treatment of SE emerged. 4, 5 Theoretically, the excellent safety profile of LEV and its broad spectrum efficacy make it a good candidate for use in frail patients with SE. Following the introduction of an intravenous preparation in 2006, some literature has accumulated on this topic. The initial case series on the use of LEV in SE reported the drug to be highly successful in terminating seizures. 4, [6] [7] [8] Subsequent studies and reviews have somewhat modulated this view, but despite this LEV is still considered one of the possible AEDs for use in the treatment of SE. However, many of the above studies describe the use of LEV as an add-on treatment in SE in addition to other AEDs, and have therefore failed to clarify the benefits of LEV as an alternative stage two AED in patients where standard treatment cannot be given. 4, 6 We are interested in the clinical problem of patients with benzodiazepine-resistant SE where phenytoin is deemed inappropriate. The clinician is then faced with the dilemma of either administrating an alternative AEDs or proceeding directly to intensive care, which also carries risks. Against this background, we wanted to clarify the evidence for the use of LEV as an alternative stage two AED in SE and undertook a systematic review of the literature. Because of the scarcity of randomized evidence regarding treatment of SE, we did not expect to find studies fit for a meta-analysis. Instead, the aim of the study Seizure 21 (2012) [233] [234] [235] [236] was to qualitatively characterize the current literature with a focus on studied patient populations, efficacy and safety.
Methods
We first searched the literature for studies describing the use of LEV as a first-line AED. The inclusion criteria were any study written in the English language describing more than two adult patients with: (1) SE, and; (2) LEV administered intravenously as the first AED, either on its own or together with or after benzodiazepines. The sought outcome measures were efficacy in terminating SE and reported adverse effects. For adverse events, we used a conservative approach and included all events reported for patients initially treated with LEV, regardless of subsequent administration of other AEDs. We also compiled information about the study populations.
An online MEDLINE search in January 2011 for ''Levetiracetam status epilepticus'' resulted in 118 articles. The abstracts were assessed and 17 studies selected for additional analysis. Nine studies met the inclusion criteria. One study was excluded because the outcome of the relevant patients could not be extracted from the reported data, leaving eight studies. 5, [7] [8] [9] [10] [11] [12] [13] To make sure that our search had adequately covered the literature, articles cited in the selected studies were also examined. This reference screening did not reveal any studies that had not been identified in the initial search. During the review process, two more relevant studies were published and added to the manuscript. 14, 15 Some methodological differences between the reviewed studies had to be reconciled for a digestible presentation. For instance, some of the larger studies describe the use of LEV in episodes of SE and the same patients may have been included multiple times.
Results
Of the ten studies included, all but one 15 were performed in Europe. In these studies, which described a total of 334 patients treated with LEV, 55 patients had received LEV alone and 279 had received LEV in conjunction with benzodiazepines. Because of the large variability in the size of the studies, their different treatment protocols, and their observational nature, a quantitative metaanalysis of the data was considered inappropriate. Instead, we focused on qualitatively describing the literature. All reviewed studies but one were observational and uncontrolled. Seven studies were retrospective and three studies were prospective, out of which one was randomized. 15 In most studies,
where that information was presented, there was a majority of focal SE among the patients receiving LEV as an alternative AED. The definition of SE varied somewhat between the studies. Some authors used a time limit of 30 min with seizure or clusters of seizures without intervening restoration of consciousness. Other authors used the more aggressive time limit of five minutes. Importantly, in a majority of the studies it was clearly stated that patients received iv LEV because standard treatment was deemed inappropriate. Doses given in the reviewed studies varied from 250 to 2500 mg. For efficacy, we relied on the definitions used by the authors. This was generally a cessation of clinical seizure activity or seizure activity on EEG within a certain time frame without the need for any additional antiepileptic drugs. The efficacy measurement for each study is shown in Table 1 . The reported efficacy (Table 2 ) was 44% in two prospective studies, and 75% in one prospective study. Efficacy ranged from 60% to 94% in the retrospective studies.
With regards to safety, none of the studies reported any serious side effects related to treatment with LEV. Sedation was the most common side effect, occurring in quantities ranging from 12.5% to 40%. All side effects are listed in Table 2 .
Discussion
Here we have reviewed the published experience of LEV as an alternative stage two AED in the treatment of SE. SE is a clinical scenario well known for its lack of randomized controlled evidence, 1 so it is no surprise that our review revealed only studies traditionally categorized as low-grade evidence -with one notable exception, Misra et al., which is discussed in detail below. Regarding study design, all studies except Misra et al. were observational and uncontrolled. The majority were retrospective and small. The main method used to find patients was retrospective analysis of the medical records for all patients treated with iv LEV during a defined period. In the reviewed studies, the reported efficacy for patients treated with LEV as a first line AED ranged from 44% to 94%. We believe that the most interesting finding in our review is that higher efficacy was reported in the retrospective studies compared to the prospective ones (Fig. 1) . This indicates a possible publication or selection bias in some of the retrospective data. For example, centers with a less favorable experience with LEV in SE might have refrained from further use of the drug and thereby publication. Another possible explanation for the large variability in efficacy is variation in the study populations and the small number of patients in some of the studies.
The differences between the prospective studies underline the need for further investigation into the use of LEV in SE. The differences between the two large prospective studies in this review, which report efficacies of 44% and 75% respectively, are most likely due to differences in patient population and treatment protocol. It is important to note that the patient populations described in the reviewed articles are most likely not representative of patients with SE in general. In at least six of the studies it is clearly stated that the reason for giving iv LEV was because standard treatment was considered inappropriate, for instance due to circulatory instability or known drug allergy. This is well in line with the clinical scenario we set out to investigate, but more importantly means that the patient population might be frailer or have more co-morbidities than patients with SE who are able to receive the standard treatment. One should therefore avoid drawing conclusions from these studies regarding the efficacy of LEV for SE in patients where standard treatment is not contraindicated, and the efficacy of LEV reported therein should not be compared with that of, for instance, phenytoin in regular patients with SE. Another important point regarding the current literature is that many of the studies were not designed to prove efficacy, but merely to publish the clinical experience with LEV. This might explain the very small number of patients in some of the case series. Finally, in many of the reviewed studies the majority of patients suffered focal seizures, which makes it even harder to draw conclusions regarding the efficacy of LEV in all patients with SE. In fact, some authors report failure of LEV in generalized SE, but good effects in non-convulsive SE. 11 Whether LEV might be of more value in treatment of focal rather than in generalized SE is a very important issue to address in future studies. With regard to safety, the data in the reported studies confirms the previous picture of LEV as a relatively safe drug, although thrombocytopenia was noted in some patients. This side effect has attracted increasing attention in recent years and should be closely monitored in future trials. 16 The most commonly reported side effect was sedation/somnolence, which is common in all treatment regimes of SE. It is important to bear in mind that in our compilation we decided to include all side effects stated for patients initially treated with LEV with or without benzodiazepines, even if those patients later received other AEDs. This conservative approach, chosen so as not to underestimate the risks associated with LEV, makes it likely that some of the reported cases of sedation were not attributed to LEV, but to benzodiazepines or other AEDs. Nonetheless, the reviewed studies support the notion that LEV is a relatively safe AED, although long-term side effects may have not emerged yet. The relatively good safety profile of the drug is underlined by the fact that the majority of the studies were performed on patients where co-morbidity prevented the use of standard treatment. We conclude that the evidence for LEV as an alternative stage two AED in SE is scarce. The number of patients described in the literature is still low and the data is largely uncontrolled and observational. The patient populations in the reviewed studies are very heterogeneous, not only regarding personal characteristics such as age, but also the etiology of the SE and the reason for selecting iv LEV as the treatment.
Pending randomized controlled data comparing the efficacy of LEV to that of phenytoin, valproic acid, and other potential firstline AEDs, the main use of LEV will most likely remain cases of SE where standard treatment is contraindicated. Given the mild side effects associated with LEV described in the reviewed studies, we think that this use might be motivated in selected cases, as suggested by the most current consensus document. 1 However, clinicians should be aware of the current paucity of evidence and be cautious in order that administration of LEV does not unduly delay progression to the next treatment stage. As indicated in one of the most recent studies, LEV might not be the first alternative AED to consider if phenytoin is contraindicated, since LEV might be less effective than both phenytoin and valproate in terminating SE.
14 It should also be noted that LEV is not licensed for use in status epilepticus, so the medico-legal situation of each specific country determines whether it is an available treatment option. In current high-quality reviews, LEV is listed as an alternative stage two AED in the treatment of SE. 1, 17 Our short review supports this notion, but also demonstrates that different centers have varying experiences with LEV, underlining the need for more randomized data before the place of LEV in treatment of SE can be properly determined.
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